What are the possible causes of a foul odor from psoriatic plaques and how should it be evaluated and managed?

Foul Odor from Psoriatic Plaques: Evaluation and Management

A foul odor emanating from psoriatic plaques most commonly indicates secondary bacterial or fungal superinfection, which requires immediate microbiological evaluation and antimicrobial therapy in addition to optimized psoriasis treatment.

Primary Causes of Malodor in Psoriasis

Bacterial Colonization and Infection

• Psoriatic plaques harbor significantly higher bacterial counts than adjacent normal skin or healthy controls, creating an environment conducive to malodor production 1
• Staphylococcus aureus nasal carriage rates are elevated in psoriatic patients compared to controls, increasing risk of skin colonization 1
• The thick scale and inflammatory milieu of psoriatic plaques provide an ideal substrate for bacterial proliferation 1

Fungal Superinfection

• Approximately 16% of psoriatic patients develop concurrent fungal infections, with dermatophytes (54%), Candida species (19.5%), and Malassezia species (15%) being the most common causative organisms 2
• Among yeasts, Malassezia restricta and Candida glabrata are the predominant species associated with psoriatic lesions 2
• Fungal pathogens can act as superantigens, perpetuating chronic inflammation while producing characteristic odors 2

Location-Specific Considerations

• Inverse psoriasis affecting intertriginous areas (axillae, genital, perineal, inframammary regions) is particularly prone to malodor due to moisture, friction, and bacterial overgrowth 3, 4
• These areas demonstrate erythematous plaques with minimal scaling but maximal maceration 3

Diagnostic Evaluation Algorithm

Immediate Assessment Steps

1. Perform potassium hydroxide (KOH) examination of scale to identify fungal hyphae or yeast forms 2
2. Obtain bacterial culture and sensitivity from the malodorous plaque to identify pathogenic organisms 1
3. Submit fungal culture if KOH is positive or clinical suspicion is high 2
4. Assess for signs of secondary infection: increased warmth, purulent drainage, satellite pustules, or rapid expansion of lesions 3

Key Diagnostic Distinctions

• Psoriatic plaques are well-demarcated with thick silvery scale on extensor surfaces, distinguishing them from tinea corporis which shows annular lesions with raised borders 4
• KOH examination is negative in uncomplicated psoriasis but positive for hyphae in dermatophyte infection 4

Management Strategy

Antimicrobial Therapy (First Priority)

• Initiate appropriate antimicrobial therapy based on culture results while continuing psoriasis treatment 2
• For confirmed fungal infection, concomitant use of antifungals with anti-inflammatory drugs represents an effective approach for managing chronic psoriatic lesions 2
• Address bacterial colonization with topical or systemic antibiotics as indicated by culture sensitivity 1

Optimizing Psoriasis Control

• For intertriginous/inverse psoriasis with malodor, use low-potency topical corticosteroids (class 6-7) to avoid atrophy in these sensitive areas 5
• Limit moderately potent corticosteroids to ≤100g per month with regular clinical review and intermittent non-steroidal alternatives 3
• Consider vitamin D analogues or topical calcineurin inhibitors for maintenance in odor-prone intertriginous zones 5, 3

Escalation for Moderate-to-Severe Disease

• If body surface area >10% or significant quality-of-life impairment exists, biologic therapies targeting TNF-α, IL-17, or IL-23 are recommended as first-line systemic options 3
• Combination of biologics with topical corticosteroids can enhance efficacy 6, 3

Critical Pitfalls to Avoid

Common Errors

• Do not attribute malodor solely to psoriasis without microbiological evaluation—this delays treatment of superinfection 2, 7
• Avoid high-potency corticosteroids in intertriginous areas where inverse psoriasis commonly occurs, as this increases infection risk and atrophy 5
• Do not overlook fungal pathogens, which are present in 16% of psoriatic patients and require specific antifungal therapy 2

Medication Considerations

• Avoid or carefully monitor beta-blockers, NSAIDs, lithium, chloroquine, and mepacrine as these can precipitate severe psoriasis flares 8, 3
• Counsel on alcohol cessation, as alcohol consumption aggravates psoriasis 8, 3

Monitoring Requirements

• Reassess within 2-4 weeks to confirm resolution of malodor and infection 5
• Screen for psoriatic arthritis (affects 25-30% of patients) and cardiovascular comorbidities during follow-up 3
• If malodor persists despite appropriate antimicrobial therapy, consider alternative diagnoses such as hidradenitis suppurativa or other conditions causing pathologic body odor 7